Dogwood Therapeutics, INC Form 4 insider transactions

Dogwood Therapeutics, Inc. reports a Form 4 filing detailing stock option transactions by Director Abel De La Rosa.

Dogwood Therapeutics, Inc. director Thomas John C acquired stock options granting the right to buy 16,800 shares.

Richard James Whitley, a Director at Dogwood Therapeutics, Inc., acquired stock options for 16,800 shares.

Director David R. Keefer of Dogwood Therapeutics, Inc. reported the acquisition of 16,800 shares of common stock via stock options.

Dogwood Therapeutics' SVP of Operations, Ralph Grosswald, was granted 82,500 stock options with an exercise price of $2.86.

Dogwood Therapeutics' Chief Financial Officer, Angela Walsh, was granted 82,500 stock options with an exercise price of $2.86.

Dogwood Therapeutics' Chief Medical Officer, Roger Michael Gendreau, was granted 82,500 stock options with an exercise price of $2.86, vesting over time.

Dogwood Therapeutics CEO Gregory Scott Duncan received a grant of 330,000 stock options with an exercise price of $2.86.

Dogwood Therapeutics CEO Gregory Scott Duncan acquired 460,000 stock options with an exercise price of $6.14, vesting over time.

Dogwood Therapeutics' Chief Financial Officer, Angela Walsh, was granted 150,000 stock options with an exercise price of $6.14, vesting over time.

Dogwood Therapeutics' SVP of Operations, Ralph Grosswald, was granted 150,000 stock options with an exercise price of $6.14, vesting over time.

Dogwood Therapeutics' Chief Medical Officer, Roger Michael Gendreau, was granted 150,000 stock options at an exercise price of $6.14.

Dogwood Therapeutics' Series A and A-1 Preferred Stock held by Sealbond and Conjoint converted into common shares, significantly altering beneficial ownership and board representation.

Dogwood Therapeutics, Inc.'s Chief Medical Officer, Roger Michael Gendreau, was granted 12,075 stock options with an exercise price of $4.71 per share, vesting over time.

Richard James Whitley, a Director at Dogwood Therapeutics, Inc., was granted 2,362 stock options with an exercise price of $4.71 per share.

Ralph Grosswald, SVP of Operations at Dogwood Therapeutics, Inc., was granted 12,075 stock options with an exercise price of $4.71 per share, vesting over time.

Dogwood Therapeutics, Inc. Director John C. Thomas reported the acquisition of 2,362 stock options with an exercise price of $4.71, exercisable from June 27, 2026, and expiring on June 27, 2035.

Dogwood Therapeutics, Inc. Chief Executive Officer Gregory Scott Duncan was granted 40,000 stock options with an exercise price of $4.71, aligning executive incentives with long-term company performance.

Dogwood Therapeutics, Inc. Director David R. Keefer acquired 2,362 stock options with an exercise price of $4.71 per share.

Dogwood Therapeutics, Inc. Chief Financial Officer, Angela Walsh, was granted 12,075 stock options with an exercise price of $4.71, vesting over a period of time.

Dogwood Therapeutics Director Abel De La Rosa acquired 2,362 stock options with an exercise price of $4.71, aligning his interests with the company's future performance.

Richard James Whitley, a Director at Dogwood Therapeutics, Inc., acquired 420 stock options with an exercise price of $4.80 per share.

David R. Keefer, a Director and 10% owner of Dogwood Therapeutics, Inc., reported the acquisition of 420 stock options with an exercise price of $4.80 per share.

Dogwood Therapeutics, Inc. Director Thomas John C was granted 420 stock options with an exercise price of $4.80 per share, exercisable starting June 18, 2026, and expiring on June 18, 2035.

Abel De La Rosa, a Director at Dogwood Therapeutics, Inc. (DWTX), was granted 420 stock options with an exercise price of $4.8 per share, aligning his interests with shareholder value.

CK Life Sciences Intl (Holdings) Inc, a 10% owner and director by deputization of Dogwood Therapeutics, acquired Series A-1 Preferred Stock through a debt exchange agreement.

Director William Pridgen acquired stock options in Virios Therapeutics, Inc. on February 26, 2024.

Director John C. Thomas acquired stock options in Virios Therapeutics, Inc. on February 26, 2024.

Richard James Whitley, a director of Virios Therapeutics, acquired stock options to purchase 4,000 shares of common stock on February 26, 2024.

Director David R. Keefer acquired stock options in Virios Therapeutics, Inc. on February 26, 2024.